Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2025 (Earliest event reported)
Reporting Period: Events occurring between January 8, 2025, and January 10, 2025.
Context: The Company, an emerging growth company, announced and executed a public offering of common stock to raise capital.
Key Financial Metrics and Transaction Details
This filing details a specific capital raise rather than periodic financial performance. Key metrics related to the transaction include:
- Shares Issued: 5,000,000 shares of Common Stock.
- Offering Price: $0.85 per share.
- Gross Proceeds: $4.25 million (before fees and expenses).
- Placement Agent Fees: 8.0% cash fee plus a 1% management fee of gross proceeds.
- Warrant Issuance: 250,000 Placement Agent Warrants (5% of shares sold) with an exercise price of $1.0625 per share.
- Closing Date: January 10, 2025.
Note: The filing does not provide updated revenue, profit, cash flow, or debt figures for the Company's operations.
Material Changes and Agreements
The primary material change is the entry into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. Key terms include:
- Lock-Up Agreements: The Company agreed not to issue additional common stock or equivalents for 15 days post-closing. Directors and executive officers are subject to a 90-day lock-up period.
- Variable Rate Transactions: The Company is restricted from entering variable rate transactions for 6 months post-closing.
- Warrant Terms: Placement Agent Warrants are exercisable 6 months after issuance and expire on the five-year anniversary of the initial exercise date. Cashless exercise is permitted in certain circumstances.
Outlook, Risks, and Management Commentary
Management Commentary: The Company utilized a shelf registration statement (Form S-3) declared effective on October 10, 2024, to facilitate this offering. The transaction was executed on a "best efforts" basis.
Risks and Contingencies:
- Dilution: The issuance of 5,000,000 new shares and 250,000 warrants will result in dilution to existing shareholders.
- Market Conditions: The offering price of $0.85 reflects current market valuations; future stock performance is subject to market volatility.
- Unregistered Securities: The Placement Agent Warrants were sold in reliance on Section 4(a)(2) of the Securities Act and Regulation D exemptions.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 9% total fee (8% cash + 1% management) and other offering expenses.
- Confirm the exact closing date and settlement of the 5,000,000 shares on January 10, 2025.
- Review the full text of the Placement Agency Agreement (Exhibit 10.1) for specific termination provisions and indemnification obligations.
- Monitor the Company's cash burn rate to assess how long the $4.25 million gross proceeds will extend the operating runway.
- Check for any subsequent filings regarding the exercise of the Placement Agent Warrants or changes to the lock-up agreements.